Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAX: Pembrolizumab and Axitinib in Metastatic RCC
NCT05263609Phase 2Withdrawn
- Sponsor
- University of Oklahoma
- Start
- Jun 2022
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, open-label trial of pembrolizumab and axitinib in renal cell carcinoma (RCC) (2 arms), sponsored by University of Oklahoma. Primary endpoints: Proportion of Patient Response at 2 years and Objective Response Rate After Axitinib at 2 years. Planned start Jun 2022; status: withdrawn.
02
Drugs
pembrolizumabaxitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05263609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263609.